Eczema other diagnostic studies

Eczema Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Eczema from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Social Impact

Future or Investigational Therapies

Case Studies

Case #1

Eczema On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Eczema

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Eczema

CDC on Eczema

Eczema in the news

Blogs on Eczema

Directions to Hospitals Treating Eczema

Risk calculators and risk factors for Eczema

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Associate Editor(s)-in-Chief:  Edzel Lorraine Co, D.M.D., M.D.

## Overview

[edit | edit source]

No particular biomarker is reliable to diagnose eczema. However, potential options include CD30, macrophage-derived chemoattractant (MDC}, thymus and activation-regulated cytokine (TARC), and interleukin-12 (IL-12) ,interleukin-16 (IL-16, interleukin-18 (IL-18), and interleukin-31 (IL-31).[1] [2] [3] [4]

## Other Diagnostic Studies of Eczema

[edit | edit source]

* No particular biomarker is reliable to diagnose eczema.
* However, potential options include:
* CD30
* Macrophage-derived chemoattractant (MDC)
* Thymus and activation-regulated cytokine (TARC)
* Interleukin-12 (IL-12)
* Interleukin-16 (IL-16)
* Interleukin-18 (IL-18)
* interleukin-31 (IL-31).

## References

[edit | edit source]

1. ↑ Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, Simpson EL; et al. (2014). "Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis". J Am Acad Dermatol. 70 (2): 338–51. doi:10.1016/j.jaad.2013.10.010. PMC 4410183. PMID 24290431.CS1 maint: Multiple names: authors list (link)
2. ↑ Kabashima K (2013). "New concept of the pathogenesis of atopic dermatitis: interplay among the barrier, allergy, and pruritus as a trinity". J Dermatol Sci. 70 (1): 3–11. doi:10.1016/j.jdermsci.2013.02.001. PMID 23473856.
3. ↑ Murat-Susić S, Lipozencić J, Zizić V, Husar K, Marinović B (2006). "Serum eosinophil cationic protein in children with atopic dermatitis". Int J Dermatol. 45 (10): 1156–60. doi:10.1111/j.1365-4632.2006.02865.x. PMID 17040428.CS1 maint: Multiple names: authors list (link)
4. ↑ Schulte-Herbrüggen O, Fölster-Holst R, von Elstermann M, Augustin M, Hellweg R (2007). "Clinical relevance of nerve growth factor serum levels in patients with atopic dermatitis and psoriasis". Int Arch Allergy Immunol. 144 (3): 211–6. doi:10.1159/000103994. PMID 17579279.CS1 maint: Multiple names: authors list (link)